(R)-3-amino-5-carboxymethyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one | 780013-20-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-3-amino-5-carboxymethyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one
• 英文别名: 2-[(3R)-3-amino-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
• CAS: 780013-20-9
• 化学式: C₁₁H₁₂N₂O₃S
• 分子量: 252.294
• InChiKey: FKJMRSNUIRKFPA-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl (2R)-6-(1-benzyloxycarbonyl-4-piperidyl)-2-methanesulfonyloxyhexanoate 、 (R)-3-amino-5-carboxymethyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one 以85%的产率得到
  参考文献：
  名称：

  KORI, MASAKUNI;ITOH, KATSUMI;SUGIHARA, HIROSADA, CHEM. AND PHARM. BULL., 35,(1987) N 6, 2319-2326

  摘要：

  DOI：

文献信息

• PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION
  申请人：PETZELBAUER Peter

  公开号：US20100081787A1

  公开（公告）日：2010-04-01

  Peptides, peptidomimetics and derivatives thereof of the general formula I: H 2 N-GHRPX 1 - β -X 4 X 5 X 6 X 7 X 8 X 9 X 10 -X 11 (I), in which X 1 -X 10 denote one of the 20 genetically coded amino acids, wherein X 8 , X 9 and X 10 may also denote a single chemical bond; X 11 denotes OR 1 in which R 1 equals hydrogen or (C 1 -C 10 ) alkyl NR 2 R 3 with R 2 and R 3 are equal or different and denote hydrogen, (C 1 -C 10 ) alkyl, or a residue —W-PEG 5-60K , in which the PEG residue is attached via a suitable spacer W to the N-atom, or a residue NH—Y-Z-PEG 5-60K , in which Y denotes a chemical bond or a genetically coded amino acids from the group S, C, K or R and Z denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, and their physiologically acceptable salts, and β denotes an amino acid, or a peptidomimetic element, which induces a bend or turn in the peptide backbone.

  通用公式I：H2N-GHRPX1-β-X4X5X6X7X8X9X10-X11(I)中的肽、肽类似物和衍生物，其中X1-X10表示20种遗传编码的氨基酸之一，其中X8、X9和X10也可以表示单一化学键；X11表示OR1，其中R1等于氢或(C1-C10)烷基NR2R3，其中R2和R3相同或不同，表示氢、(C1-C10)烷基，或者残基—W-PEG5-60K，其中PEG残基通过适当的间隔物W连接到N-原子，或者残基NH—Y-Z-PEG5-60K，其中Y表示化学键或来自S、C、K或R组的遗传编码氨基酸，Z表示间隔物，通过该间隔物可以连接聚乙二醇（PEG）残基，并且它们的生理上可接受的盐，β表示氨基酸或诱导肽骨架中弯曲或转弯的肽类或肽类似元素。
• Condensed seven-membered ring compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0156455A2

  公开（公告）日：1985-10-02

  Novel condensed seven-membered ring compounds of the formula: [wherein R1 and R2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R3 and R5 are independently hydrogen, lower alkyl or aralkyl; R4 is hydrogen or lower alkyl; R6 is a condensed or non-condensed hetero-alicyclic containing at least one atom of N, 0 and S as a ring-forming atom which may be substituted; A is an alkylene chain; n is 1 or 2] and salts thereof. These compounds exhibit inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases, such as hypertension, cardiopathy and cerebral apoplexy.

  式中 R1 和 R2 独立地为氢、卤素、三氟甲基、低级烷基或低级烷氧基，或二者共同形成三亚甲基或四亚甲基；R3 和 R5 独立地为氢、低级烷基或芳烷基；R4 为氢或低级烷基；R6 为缩合或非缩合杂脂环，至少含有一个 N、0 和 S 原子作为成环原子，可被取代；A 为亚烷基链；n 为 1 或 2]及其盐。 这些化合物对血管紧张素转换酶等具有抑制活性，具有诊断、预防和治疗高血压、心肌病和脑中风等循环系统疾病的价值。
• Dual action inhibitors
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0599444B1

  公开（公告）日：1998-01-28
• EP0783002A2
  申请人：——

  公开号：EP0783002A2

  公开（公告）日：1997-07-09
• PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION
  申请人：Fibrex Medical Research & Development GmbH

  公开号：EP2274328A1

  公开（公告）日：2011-01-19